Allogene Therapeutics ALLO Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's operating lease ROU assets?
- Allogene Therapeutics (ALLO) reported operating lease ROU assets of 6.5% in Q1 2026.
- How has Allogene Therapeutics's operating lease ROU assets changed year-over-year?
- Allogene Therapeutics's operating lease ROU assets increased by 3.8% year-over-year, from 6.3% to 6.5%.
- What is the long-term trend for Allogene Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Allogene Therapeutics's operating lease ROU assets has grown at a -0.7% compound annual growth rate (CAGR), from 4,129,500,000% to 3,988,800,000%.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.